Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 878183
                    [Title] => Quality of life for prostate cancer treatments
                    [Summary] => 
The 3-year results of a nonra-ndomized trial from Spain reveal different patterns of adverse events after three leading treatments for localized prostate cancer.

                    [DatePublished] => 2012-12-02 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

        )

)

EXPANDED PROSTATE CANCER INDEX COMPOSITE

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 878183
                    [Title] => Quality of life for prostate cancer treatments
                    [Summary] => 
The 3-year results of a nonra-ndomized trial from Spain reveal different patterns of adverse events after three leading treatments for localized prostate cancer.

                    [DatePublished] => 2012-12-02 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

        )

)

abtest

Quality of life for prostate cancer treatments

By YOUR DOSE OF MEDICINE | By Charles C. Chante MD | December 2, 2012 - 12:00am

The 3-year results of a nonra-ndomized trial from Spain reveal different patterns of adverse events after three leading treatments for localized prostate cancer.

Opinion